SCHAUMBURG, Ill., May 18, 2015 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB:WCUI), today announced the appointment of Seth B. Forman, MD as Medical Director of Psoria-Shield, Inc. (PSI). Dr. Forman is an internationally recognized expert on the treatment of psoriasis and other auto-immune skin diseases, as well as an early adopter of the Psoria-Light®. As PSI continues with its commercialization and sales program, Dr. Forman's knowledge and expertise will be invaluable to help position the Psoria-Light® device for use at dermatological centers.
Seth B. Forman, MD is a board-certified dermatologist and dermatopathologist practicing in Tampa, Florida. He is also a leading clinical researcher, educator and speaker for atopic dermatitis (eczema), psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, and actinic keratosis. He has worked with AstraZeneca, AbbVie, Abbott, Celgene, Genentech, Janssen, Medimmune, and Regeneron. His expertise is recognized worldwide.
Dr. Forman's dermatology center, The Forman Dermatology and Skin Cancer Institute, integrated the Psoria-Light® within its practice to treat psoriasis, eczema, and vitiligo, and has reported excellent results.
"It has proven itself as a safe, reliable, and powerful alternative to existing treatment solutions such as the Excimer Laser," stated Dr. Forman. "With the Psoria-Light®, we have been able to treat more patients with greater efficacy. Simply put, there is nothing better on the market today when it comes to treating these auto-immune skin diseases, and we believe that targeted phototherapy delivered by this device should become the standard of care," he added.
Dr. Forman has been featured on the nationally syndicated talk show "The Doctors," MSNBC and Glamour magazine. He's been a regular commentator on Tampa stations 10 News (WTSP, CBS affiliate) and has been featured by News Channel 8 (WFLA, NBC affiliate) and ABC Action News (WFTS) as well as the Tampa Bay Times and the Tampa Tribune. The ABC Action News clips can be found at:
High Tech Skin Treatment Helps Psoriasis and Eczema
UV Technology Reverses Pigmentation Loss from Vitiligo
Dr. Forman operates Forward Clinical Trials, Inc. (www.forwardclinicaltrials.com), which conducts leading edge medical research and clinical studies for various skin conditions and diseases such as psoriasis, eczema, vitiligo, and more through its two (2) locations in the Tampa area. At the Forman Dermatology and Skin Cancer Institute, Dr. Forman has successfully administered thousands of treatments using the Psoria-Light® to suffering patients. Noteworthy, these treatments have been conducted with little to no operational down time and minimal maintenance costs, using the Psoria-Light®.
"This speaks volumes to us and is a testament to the quality, reliability, and capability of our device," stated John Yorke, Managing Director of The Medical Alliance (TMA) and WCUI's Joint Venture Partner (PDC, LLC). "Dr. Forman's appointment as Medical Director of PSI is a significant step forward as we continue to expand the company's market exposure. His insight and clinical experience will allow us to maximize Psoria-Light's efficacy to practitioners," added Yorke.
Dr. Forman graduated medical school at the Medical College of Virginia in Richmond, VA. He then completed his residency in dermatology at the Medical College of Virginia. He was selected and served as Chief Resident during his final year of training. Following that, he completed an advanced fellowship in dermatopathology at the Geisinger Medical Center in Danville, PA.
About Wellness Center USA, Inc.
Wellness Center USA, Inc. (www.wellnesscenterusa.com) is a hybrid healthcare company that combines best in class technologies, software, devices, providers, protocols, goods, and services. It was created to address important healthcare and wellness needs via breakthrough solutions, all centered around the "well-being of the body and mind". Wellness Center USA, Inc. is the parent company of three businesses reporting consolidated: Stealth Mark, National Pain Centers, and Psoria-Shield.
Safe Harbor Statement:
Certain statements and projections contained in this presentation that are not statements or financial results of historical fact constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements and projections include statements regarding any proposed exchange transactions, the anticipated closing date of such transactions and future results following a closing of the transactions. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like "believe," "expect," "anticipate," "pending," "estimate," and "intend" or future or conditional verbs such as "will," "would," "should," "could," or "may." While it is not possible to identify all factors, risks and uncertainties that might relate to, affect or arise from the proposed transactions and plans which might cause actual results to differ materially from expected results, such factors, risks and uncertainties include delays in completing the transactions, difficulties in integrating operations following the transactions, difficulties in manufacturing and delivering products, potential market rejection of products or services, increased competitive pressures, changes in general economic conditions, legislative and regulatory changes that adversely affect the business in which the parties are engaged, changes in the securities markets and other factors, risks and uncertainties disclosed from time to time in documents that the Company files with the SEC.